NAMSW · Bull vs Bear

The case for and the case against NewAmsterdam Pharma Company N.V., each point drawn from public SEC filings — who’s buying, the red flags, and the health score. No opinion, no price call. Read both sides, then pick yours.

the bull case // 2

Strong bankruptcy safety

Altman Z: safe zone

SEC XBRL

Strong cash position

self-funding

SEC XBRL

the bear case // 3

Weak fundamentals

Piotroski F-Score of 2/9 — most quality checks are failing.

SEC filing ↗

One-sided insider selling

9 insider sales and no open-market buys in the recent window.

SEC filing ↗

Insiders are selling

9 insider sales recently with no offsetting open-market buys.

SEC Form 4 →

where do you land on NAMSW?

Bull Bear

Saved on this device. Your call, from the evidence above — not a recommendation.

Educational only — not financial adviceand never a recommendation to buy or sell. Both sides are built from public SEC filings (Form 4, STOCK Act, 13F, XBRL financials), which lag 40–90 days; absence of a red flag is not a clean bill of health.